(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
Artemis 2 astronauts reveal adorable zero-g indicator 'Rise' | Space photo of the day for March 31, 2026- Spanish bishops and government sign deal for compensation of church sexual abuse victims
- Director of Swiss hospital describes the rush to treat the injured from Alpine resort bar fire
- 5 Eating routine Well disposed Snacks to Keep You Fulfilled
- Asia's Noteworthy Destinations: A Voyager's Aide
- Poll: By a 2-to-1 margin, Americans say Trump has done more to raise prices than lower them
- Volunteers aiding humpback whale stranded in Baltic get death threats
- Dominating Your Cash: The Fundamental Manual for Overseeing Individual accounting records
- This cafe takes orders in sign language. It's cherished by the Deaf community
